Search 

Abveris is a Massachusetts-based company that provides industry-leading solutions for therapeutic and reagent antibody developements. We have built a strong reputation for our ability to deliver outstanding science. Based on our proprietary hyperimmune mouse models, DiversimAb mouse, and a Beacon-based single B cell screening platform, we have custom-built gene-to-antibody solutions to support development efforts for therapeutic antibodies against difficult targets such as GPCR, ion channels, glycan targets. Abveris is rapidly expanding its antibody discovery capabilities and geographical presence to work with more emerging biotech to discover therapeutics for novel targets.

AnGes is a commercial-stage biopharmaceutical company that focuses on the development and commercialization of gene-based medicines including gene therapy, oligonucleotide drugs and DNA vaccines.
The company's lead product is Collategene for critical limb ischemia (CLI), the severest form of peripheral arterial disease (PAD), for which obtained conditional approval in Japan on March 2019. Collategene is a gene therapy product utilizing therapeutic angiogenesis by hepatocyte growth factor (HGF) gene expression. Our second project is NF-kB decoy oligonucleotide, for which a phase 1b study for low back pain commenced in February 2018 in the US. AnGes also conducting a phase I/II study for DNA vaccine for the treatment of hypertension.
We are also developing a DNA vaccine for COVID-19 which we plan to start Phase 3 from early next year.

Aposave is the global pharmaceutical and healthcare services division of the Abacus Medicine Group.

The company mission is to assist patients with unmet medical needs get access to innovative new medicines, while assisting the manufacturers to maximise the clinical and commercial potential of their assets.

Our promise to healthcare and pharmaceutical customers is to provide a new generation of healthcare and pharmaceutical services to support their new generation of pharmaceutical products throughout the 2020’s and beyond.

To do this Aposave has developed a market leading range of services focused on providing access to medicines around the world. Working across the lifecycle in partnership with pharmaceutical and biotechnology companies Aposave creates and delivers innovative solutions that ensure patients can get timely access to the medicines they need, whilst helping pharmaceutical and biotechnology companies achieve their clinical and commercial objectives.
Aposave has a range of services to support the efficient running of clinical trials called Clinical Trial Solutions (CTS). This is an area where there are great synergies with our parent company, Abacus Medicine. The Abacus Medicine Group holds over 4500 marketing authorisations, and this provides Aposave with unrivalled access to the medicines required to support the running of clinical trials. In addition, Aposave has developed some unique approaches to minimising wastage of products that have expired or are no longer required for a trial.
Aposave has extensive knowledge and experience in managing the distribution of specialty medicines, and this service line is called Specialty Commercial Distribution (SCD). Higher value, lower volume specialty medicines often do not sit well with the traditional distribution model, and this is where our team of experts develop innovative solutions to help ensure patients have access, while maintaining the commercial requirements of our clients.
Aposave is a strategic partner to the pharmaceutical and biotech industry. Aposave Access Programs (AAP) provide a framework for a partnership where Aposave creates, implements, and manages a program on behalf of a drug manufacturer to provide access to their drug in countries where it is not commercially available. This can be either in the prelaunch, or the post launch stage of the product lifecycle. Each program is designed to meet the specific needs of the manufacturer.
The final service that Aposave provides is very much focussed on the patient, and as such is called Individual Access Requests (IAR). Patients with an unmet medical need often require access to a medicine that is not commercially available in the country where they live. When the customer service team at Aposave receive such a request from a healthcare professional, if we do not already have the product in stock, we find a source of the product and ensure we deliver it, in compliance with appropriate regulations, to the relevant medical establishment ready for the patient to receive treatment.

BalinBac Therapeutics, Inc. is a clinical stage biopharmaceutical development company headquartered in Princeton, New Jersey, focused on rapidly bringing both repurposed and new antivirals and antibiotics to market. BalinBac started working on coronavirus drug solutions in January 2020 when the team predicted the impact of the COVID-19 pandemic.

Our scientists and therapeutics development executives have a wealth of working knowledge in the pharmaceutical industry and have a track record of successfully bringing key antiviral and antibacterial drugs to market. We know how to rapidly get drugs to patients and what it takes to get this work done quickly.

Bioindustry Park “Silvano Fumero” is an Italian scientific and technological park, specialized in Life Sciences, located in the Piedmont region, near Turin. Bioindustry Park promotes and develops Life Sciences research and innovation by hosting and supporting companies, start-ups and research institutions. Bioindustry Park offers a full range of services aimed at the creation and development of life sciences and health care start-up and spin-off companies not only by providing laboratories and facilities, but also through valuable scientific and business support services. Bioindustry Park “Silvano Fumero” is also the managing company of bioPmed (http://www.biopmed.eu), the Piedmont health care innovation cluster that involves private and public actors in the pharmaceutical, biotech, medtech and eHealth sectors. BioPmed gathers about 100 companies, touching the whole value chain: from research and academic institutions and foundations, to start-ups, SMEs, private and public hospitals and healthcare centers.

At Biolingus, we believe we can make life better for many people in the world, not just in rich countries, but across the globe.
BioLingus is an award-winning Swiss biotech company spearheading the development of oral (sublingual) and mucosal delivery of peptides and proteins. Our technology is "inspired by nature" using applied bio-engineering, resulting in novel bio-mimetic materials for drug delivery. Our company focusses on the development of its own products on the treatment of chronic diseases, such as diabetes, obesity and inflammatory diseases.
BioLingus’ main office is in Switzerland, with satellite companies in Hong Kong and Australia.
See also video made by the Swiss Chinese Chamber of Commerce : https://www.linkedin.com/posts/yvesdecadt_icbc-vischer-gunvor-activity-6737745258496434176-8BZc

Bioxis, creates biomaterial scaffolds that help regenerate tissues, improve patient outcomes, and provide better healthcare opportunities for doctors. We are focused on developing medical devices based on patented biomaterials technology with potentially accelerated pathways to the aesthetic dermatology market.

Our lead medical device candidate MTI-12 is currently at the pre-clinical stage for aesthetic indications; and our hyaluronic acid-based dermal filler brand, CYTOSIAL, has established into exclusive distribution agreements with distributors in Europe and Asia.

CarthaGenetics® provides consulting services to rare diseases, advanced therapies, and orphan drugs companies who want to step in the complex European markets (including Turkey) and the fast-growing North African markets. CarthaGenetics® was founded in 2004 by Philippe Carteron, on the basis of his personal commitment to the treatment of orphan diseases (rare & mostly genetic diseases) across Western Europe, Turkey & North Africa.
CarthaGenetics® has worked for the most prestigious biotech and pharma companies, as Alexion, Alnylam, Amicus, Biogen, BioMarin, FoldRX/Pfizer, Genzyme, Horizon, Insmed, Orchard, PTC, RegenXbio, Shire, Ultragenyx, as well as for Turkish Ministry of Health and Turkish Pharmacist Association (TEB). CarthaGenetics® is focused on innovative medicines, including cell and gene therapies and has 3 main areas of expertise:

1) Speed up the enrollment in Clinical Trial(s) through patient identification in cooperation with CROs:
- Our direct presence in countries with high birth numbers as Turkey, Algeria, Tunisia, Morocco is increasing the chances to complete enrollment in a shorter time.
- Our strong network among Pediatricians, Metabolicians, (Pediatric) Neurologists, Lipidologists, (Pediatric) Nephrologists, Geneticists, Hematologists and Oncologists will speed up patients identification.

2) Early Access Program (EAP or NPP) including Compassionate Use and Named Patient Sales (NPS) in countries where such programs are allowed as for instance:
- ATU in France
- Law 648 / Law 326 in Italy
- Endikasyon Dışı Kullanım Kılavuzu in Turkey

3) Biosimilars of Orphan Drugs for North Africa where there is no Orphan Drug exclusivity, representing a population about 100M. For any question please send us a message on contact@carthagenetics.com or contact us at our Swiss Headquarter +41 22 575 31 31 and visit our website at www.carthagenetics.com

CarthaGenetics® is directly present in Switzerland, France, Germany, Italy, Spain, Turkey as well as in Algeria and Tunisia

Cello Health BioConsulting, previously Defined Health, is a knowledge-based consultancy deeply rooted in science and the unique and ever-evolving challenges and opportunities facing the biopharma industry. We provide strategic advice for corporate growth strategy, disease area selection, indication prioritization, early market access strategy and early value profile development. Cello Health BioConsulting is known for “unconventional insight” – forward thinking, independent,
objective and actionable strategic advice to realize value across all therapeutic areas and stages of
development.